Historical record - last NADAC effective date: 11/20/2019
Product Information
RIVASTIGMINE 3 MG CAPSULE is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.3645 per EA under NDC 75834013460. Its NADAC has been published 95 times since Feb 14, 2018.
FDA first approved this application on Feb 13, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the RIVASTIGMINE TARTRATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
3 mg/1
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834013460
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
11/20/2019
Active Ingredients
RIVASTIGMINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA203844FDA Approved
2/13/2017
TE Code
AB
On Market Since
9/4/2017
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 3 MG CAPSULE has been published 95 times since Feb 14, 2018, and over the history we have for it it has declined 34.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3645 per EA |
|---|---|
| All-time high | $0.7031 (Apr 11, 2018) |
| All-time low | $0.3249 (Jun 19, 2019) |
| Median price | $0.3944 |
| Average price | $0.4281 |
| Largest weekly change | -35.9% (Apr 18, 2018) |
| Weeks tracked | 95 |
| Tracking since | Feb 14, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-34.4%
Last surveyed Dec 4, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 59% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 3 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 3 MG CAPSULE, manufactured by Nivagen Pharmaceuticals Inc., is $0.3645 per EA (NDC 75834013460), effective Dec 4, 2019.
How has the price of RIVASTIGMINE 3 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 3 MG CAPSULE has declined 34.4%. It has been tracked across 95 weekly CMS publications since Feb 14, 2018.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 3 MG CAPSULE?
Since Feb 14, 2018, the NADAC for RIVASTIGMINE 3 MG CAPSULE has ranged from a low of $0.3249 (Jun 19, 2019) to a high of $0.7031 (Apr 11, 2018), with a median of $0.3944 per EA.
Are there cheaper alternatives to RIVASTIGMINE 3 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIVASTIGMINE 3 MG CAPSULE, is $0.1494 per EA — about 59% below RIVASTIGMINE 3 MG CAPSULE.
Who manufactures RIVASTIGMINE 3 MG CAPSULE?
RIVASTIGMINE 3 MG CAPSULE (NDC 75834013460) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.